Trial
NCT01650350
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Brown University
Collaborators
—
Condition
Melanoma
Intervention
Naltrexone
Why stopped
Study stopped 10/24/13 secondary to lack of patients/slow enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-04